COLUMBIA, Md.--(BUSINESS WIRE)--Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading stem cell therapeutic company, announced today that it has closed an $11.8 million private placement of its common stock and eliminated through conversion, $18.8 million of debt. No fees or commissions were paid in either transaction.